| Literature DB >> 27274104 |
N Jones1, J Kiely2, B Suraci3, D J Collins2, D de Lorenzo4, C Pickering5, K A Grimaldi5.
Abstract
Association studies have identified dozens of genetic variants linked to training responses and sport-related traits. However, no intervention studies utilizing the idea of personalised training based on athlete's genetic profile have been conducted. Here we propose an algorithm that allows achieving greater results in response to high- or low-intensity resistance training programs by predicting athlete's potential for the development of power and endurance qualities with the panel of 15 performance-associated gene polymorphisms. To develop and validate such an algorithm we performed two studies in independent cohorts of male athletes (study 1: athletes from different sports (n = 28); study 2: soccer players (n = 39)). In both studies athletes completed an eight-week high- or low-intensity resistance training program, which either matched or mismatched their individual genotype. Two variables of explosive power and aerobic fitness, as measured by the countermovement jump (CMJ) and aerobic 3-min cycle test (Aero3) were assessed pre and post 8 weeks of resistance training. In study 1, the athletes from the matched groups (i.e. high-intensity trained with power genotype or low-intensity trained with endurance genotype) significantly increased results in CMJ (P = 0.0005) and Aero3 (P = 0.0004). Whereas, athletes from the mismatched group (i.e. high-intensity trained with endurance genotype or low-intensity trained with power genotype) demonstrated non-significant improvements in CMJ (P = 0.175) and less prominent results in Aero3 (P = 0.0134). In study 2, soccer players from the matched group also demonstrated significantly greater (P < 0.0001) performance changes in both tests compared to the mismatched group. Among non- or low responders of both studies, 82% of athletes (both for CMJ and Aero3) were from the mismatched group (P < 0.0001). Our results indicate that matching the individual's genotype with the appropriate training modality leads to more effective resistance training. The developed algorithm may be used to guide individualised resistance-training interventions.Entities:
Keywords: DNA; Endurance; Genotype; Personalized training; Polymorphism; Power
Year: 2016 PMID: 27274104 PMCID: PMC4885623 DOI: 10.5604/20831862.1198210
Source DB: PubMed Journal: Biol Sport ISSN: 0860-021X Impact factor: 2.806
List of genetic variants analysed by DNAFit Peak Performance Algorithm™
| Gene | Full name | Functions and associated phenotypes | Polymorphism | Endurance or power related allele | References |
|---|---|---|---|---|---|
|
| Angiotensin I converting enzyme | Regulates circulatory homeostasis through the synthesis of vasoconstrictor angiotensin II and the degradation of vasodilator kinins. | Alu I/D (rs4646994) | Endurance: I |
[ |
|
| α-actinin-3 | Stabilizes the muscle contractile apparatus in fast-twitch muscle fibres. | Arg577Ter (rs1815739 C/T) | Endurance: 577Ter (T) |
[ |
|
| β-2 adrenoreceptor | Plays a pivotal role in the regulation of the cardiac, pulmonary, vascular, endocrine and central nervous system. | Gly16Arg (rs1042713 G/A) | Endurance: 16Arg (A) |
[ |
| Gln27Glu (rs1042714 C/G) | Endurance: Gln27 (C) |
[ | |||
|
| Angiotensinogen | Angiotensinogen is an essential component of the renin-angiotensin system that regulates vascular resistance and sodium homeostasis, and thus determining blood pressure. | Met235Thr (rs699 T/C) | Power: 235Thr (C) |
[ |
|
| Bradykinin receptor B2 | Involved in the endothelium-dependent vasodilation. | rs1799722 C/T | Endurance: T |
[ |
|
| Collagen, type V, α1 | Encodes the pro-α1 chain of type V collagen, the rate-limiting component of the of type V collagen trimer assembly. | rs12722 C/T (BstUI) | Endurance: T |
[ |
|
| C-reactive protein, pentraxin-related | Involved in several host defense related functions based on its ability to recognize damaged cells and to initiate their elimination in the blood. | rs1205 A/G | Endurance: A |
[ |
|
| GA binding protein transcription factor, β subunit 1 (nuclear respiratory factor 2) | Encodes a transcriptional regulator of genes involved in activation of cytochrome oxidase expression and nuclear control of mitochondrial function. | rs7181866 A/G | Endurance: G |
[ |
|
| Interleukin-6 | IL-6 is a pleiotropic cytokine expressed in immune and muscle cells. Involved in a wide variety of biological functions, including regulation of differentiation, proliferation and survival of target cells. | -174 C/G (rs1800795) | Power: G |
[ |
|
| Peroxisome proliferator-activated receptor α | Regulates liver, heart and skeletal muscle lipid metabolism, glucose homeostasis, mitochondrial biogenesis, cardiac hypertrophy. | rs4253778 G/C | Endurance: G |
[ |
|
| Peroxisome proliferator-activated receptor γ coactivator 1 α | Regulates fatty acid oxidation, glucose utilization, mitochondrial biogenesis, thermogenesis, angiogenesis, formation of muscle fibers. | Gly482Ser (rs8192678 G/A) | Endurance: Gly482 (G) |
[ |
|
| Thyrotropin-releasing hormone receptor | Stimulates the release of thyroxine, which is important in developing skeletal muscle. | rs16892496 A/C | Power (muscle mass): C |
[ |
|
| Vitamin D receptor | Involved in sustaining normocalcemia by inhibiting the production of parathyroid hormone and has effects on bone and skeletal muscle biology. | BsmI A/G (rs1544410) | Power: A |
[ |
|
| Vascular endothelial growth factor A | Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. | rs2010963 G/C | Endurance: C |
[ |
Genotype distributions and minor allele frequencies of candidate genes in athletes of two studies.
| Gene and variation | Study | Genotypes | MAF,% |
| ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| AA | AB | BB | ||||||||
|
| S1 | DD | 10 | ID | 11 | II | 7 | I | 44.6 | 0.2776 |
| S2 | 14 | 16 | 9 | 43.6 | 0.3005 | |||||
|
| S1 | CC | 8 | CT | 10 | TT | 10 | T | 53.6 | 0.1356 |
| S2 | 12 | 21 | 6 | 42.3 | 0.5199 | |||||
|
| S1 | GG | 16 | GA | 10 | AA | 2 | A | 25.0 | 0.8011 |
| S2 | 21 | 13 | 5 | 29.5 | 0.2153 | |||||
|
| S1 | CC | 5 | CG | 15 | GG | 8 | G | 55.4 | 0.6572 |
| S2 | 14 | 16 | 9 | 43.6 | 0.3005 | |||||
|
| S1 | TT | 9 | TC | 15 | CC | 4 | C | 41.1 | 0.5723 |
| S2 | 17 | 17 | 5 | 34.6 | 0.8171 | |||||
|
| S1 | CC | 9 | CT | 14 | TT | 5 | T | 42.9 | 0.9122 |
| S2 | 15 | 17 | 7 | 39.7 | 0.5745 | |||||
|
| S1 | TT | 8 | TC | 17 | CC | 3 | C | 41.1 | 0.1784 |
| S2 | 13 | 17 | 9 | 44.9 | 0.4576 | |||||
|
| S1 | GG | 12 | GA | 12 | AA | 4 | A | 35.7 | 0.7243 |
| S2 | 21 | 12 | 6 | 30.8 | 0.0828 | |||||
|
| S1 | AA | 27 | AG | 1 | GG | 0 | G | 1.8 | 0.9233 |
| S2 | 36 | 2 | 1 | 5.1 | 0.0031 | |||||
|
| S1 | GG | 10 | GC | 13 | CC | 5 | C | 41.1 | 0.8289 |
| S2 | 17 | 16 | 6 | 35.9 | 0.4977 | |||||
|
| S1 | GG | 21 | GC | 5 | CC | 2 | C | 16.1 | 0.0736 |
| S2 | 26 | 11 | 2 | 19.2 | 0.5653 | |||||
|
| S1 | GG | 7 | GA | 18 | AA | 3 | A | 42.9 | 0.0982 |
| S2 | 15 | 17 | 7 | 39.7 | 0.5745 | |||||
|
| S1 | AA | 14 | AC | 9 | CC | 5 | C | 33.9 | 0.1342 |
| S2 | 15 | 17 | 7 | 39.7 | 0.5745 | |||||
|
| S1 | GG | 11 | GA | 16 | AA | 1 | A | 32.1 | 0.1009 |
| S2 | 16 | 11 | 12 | 44.9 | 0.0073 | |||||
|
| S1 | GG | 13 | GC | 11 | CC | 4 | C | 33.9 | 0.5126 |
| S2 | 18 | 18 | 3 | 30.8 | 0.6028 | |||||
Note: MAF - minor allele frequency; S1 - Study 1; S2 - Study 2.
PHW < 0.05 - not consistent with Hardy-Weinberg equilibrium.
Intergroup comparisons of CMJ increases (%) in response to high- or low-intensity training
| Group | Increase in CMJ,% | P1 | |||
|---|---|---|---|---|---|
| Low-intensity RT | P2 (paired test) | High-intensity RT | P2 (paired test) | ||
| Study 1 | |||||
| All athletes (n = 28) | 6.4 (5.8) | 0.0009 | 4.1 (8.1) | 0.131 | 0.369 |
| Athletes with P genotype (n = 11) | 3.8 (5.0) | 0.156 | 7.0 (6.7) | 0.125 | 0.429 |
| Athletes with E genotype (n = 17) | 8.2 (5.9) | 0.0078 | 2.2 (8.8) | 0.813 | 0.067 |
| P3 = 0.272 | P3 = 0.353 | ||||
| Study 2 | |||||
| All athletes (n = 39) | 4.6 (4.3) | 0.0056 | 5.0 (4.7) | <0.0001 | 0.932 |
| Athletes with P genotype (n = 17) | 1.0 (4.6) | 0.578 | 7.1 (5.9) | 0.0059 | 0.0046 |
| Athletes with E genotype (n = 22) | 7.1 (1.0) | 0.002 | 3.2 (2.5) | 0.0005 | 0.0008 |
| P3 = 0.0002 | P3 = 0.0056 | ||||
| Studies 1 and 2 | |||||
| All athletes (n = 67) | 5.4 (5.0) | <0.0001 | 4.6 (6.1) | 0.0002 | 0.547 |
| Athletes with P genotype (n = 28) | 2.3 (4.8) | 0.1465 | 7.1 (5.9) | 0.0006 | 0.0052 |
| Athletes with E genotype (n = 39) | 7.6 (4.0) | <0.0001 | 2.8 (5.7) | 0.051 | 0.0012 |
| P3 = 0.0022 | P3 = 0.0098 | ||||
Note: P < 0.05 - statistically different values between groups
P - power; E - endurance, RT - resistance training. P1 - comparison between athletes with different training types (i.e. low-intensity vs. high-intensity); P2 - significant increases in CMJ (paired test); P3 - comparison between athletes with different genotype profiles (i.e. power genotype vs. endurance genotype) of the same training modality
Intergroup comparisons of Aero3 increases (%) in response to high- or low-intensity training
| Group | Increase in Aero3,% | P1 | |||
|---|---|---|---|---|---|
| Low-intensity RT | P2 (paired test) | High-intensity RT | P2 (paired test) | ||
| Study 1 | |||||
| All athletes (n = 28) | 2.6 (3.1) | 0.0103 | 4.4 (4.4) | 0.0017 | 0.618 |
| Athletes with P genotype (n = 11) | 2.0 (4.3) | 0.3125 | 6.0 (3.9) | 0.0625 | 0.178 |
| Athletes with E genotype (n = 17) | 3.0 (2.2) | 0.0078 | 3.4 (4.6) | 0.0391 | 0.541 |
| P3 = 0.776 | P3 = 0.284 | ||||
| Study 2 | |||||
| All athletes (n = 39) | 5.8 (3.7) | <0.0001 | 4.2 (3.3) | <0.0001 | 0.218 |
| Athletes with P genotype (n = 17) | 1.7 (0.5) | 0.0156 | 6.8 (2.5) | 0.002 | 0.002 |
| Athletes with E genotype (n = 22) | 8.7 (1.6) | 0.002 | 2.1 (2.3) | 0.0161 | <0.0001 |
| P3 = 0.0001 | P3 = 0.002 | ||||
| Studies 1 and 2 | |||||
| All athletes (n = 67) | 4.3 (3.8) | <0.0001 | 4.3 (3.7) | <0.0001 | 0.711 |
| Athletes with P genotype (n = 28) | 1.8 (2.8) | 0.0171 | 6.5 (2.9) | <0.0001 | 0.0004 |
| Athletes with E genotype (n = 39) | 6.0 (3.5) | <0.0001 | 2.6 (3.3) | 0.0004 | 0.0013 |
| P3 = 0.0004 | P3 = 0.0026 | ||||
Note: P < 0.05 - statistically different values between groups
P - power; E - endurance, RT - resistance training. P1 - comparison between athletes with different training types (i.e. low-intensity vs. high-intensity); P2 - significant increases in Aero3 (paired test); P3 - comparison between athletes with different genotype profiles (i.e. power genotype vs. endurance genotype) of the same training modality
Comparisons of CMJ and Aero3 increases (%) in response to resistance training between matched and mismatched groups.
| Study | Group | P3 | |||
|---|---|---|---|---|---|
| Matched athletes | Mismatched athletes | ||||
| Study 1 | n =14 | P1 (paired test) | n = 14 | P2 (paired test) | |
| Change in CMJ,% | 7.8 (5.9) | 0.0005 | 2.9 (7.2) | 0.175 | 0.0596 |
| Change in Aero3,% | 4.0 (3.1) | 0.0004 | 2.8 (4.3) | 0.0134 | 0.2456 |
| Study 2 | n =20 | n = 19 | |||
| Change in CMJ,% | 7.1 (4.1) | <0.0001 | 2.4 (3.5) | 0.0053 | <0.0001 |
| Change in Aero3,% | 7.7 (2.2) | <0.0001 | 1.9 (1.8) | 0.0004 | <0.0001 |
| Studies 1 and 2 | n =34 | n =33 | |||
| Change in CMJ,% | 7.4 (4.9) | <0.0001 | 2.6 (5.3) | 0.0152 | <0.0001 |
| Change in Aero3,% | 6.2 (3.2) | <0.0001 | 2.3 (3.1) | <0.0001 | <0.0001 |
Note: P1 and P2 < 0.05 - significant increases in CMJ and Aero3 (paired test); *P3 < 0.05 - significant difference between matched and mismatched groups. Matched athletes - high-intensity trained with endurance genotype or low-intensity trained with power genotype; mismatched athletes - high-intensity trained with power genotype or low-intensity trained with endurance genotype.